<DOC>
	<DOCNO>NCT00103116</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's white blood cell allogeneic tumor cell may make body build effective immune response kill tumor cell . PURPOSE : This phase II trial study well vaccine therapy work treat patient stage I , stage II , stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage I , Stage II , Stage III Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine immunologic effect adjuvant vaccine therapy comprise autologous dendritic cell load allogeneic non-small cell lung cancer ( NSCLC ) cell patient unresectable stage IIIA IIIB , resect stage I-IIIB NSCLC . - Determine potential clinical efficacy vaccine patient . OUTLINE : This open-label study . Patients stratify accord type prior primary therapy ( surgical v nonsurgical ) . Patients undergo leukapheresis 3-4 hour harvest mononuclear cell production dendritic cell ( DC ) . DC pulse allogeneic non-small cell lung cancer cell produce autologous dendritic cell vaccine . Patients receive vaccine intradermally month 2 month absence disease recurrence unacceptable toxicity . Patients follow monthly 4 month , every 6 month 2 year , periodically thereafter . PROJECTED ACCRUAL : A total 60 patient ( 30 per stratum ) accrue study within 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer ( NSCLC ) Meets 1 follow stage criterion : Completely resect stage IIIIB disease Underwent surgical resection &gt; 4 week ≤ 4 year ago Unresectable stage IIIA IIIB disease AND previously treat definitive radiotherapy chemotherapy &gt; 6 week ago Bronchoalveolar carcinoma allow Clinically stable disease chest xray CT scan within past 6 week No progressive disease No malignant pleural pericardial effusion PATIENT CHARACTERISTICS : Age 18 80 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Hemoglobin ≥ 9.0 g/dL Hepatic Bilirubin ≤ 2.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN No known history infectious hepatitis Renal Creatinine ≤ 3 mg/dL Ionized calcium ≥ 0.9 mmol/L ( may replace ) Cardiovascular No known New York Heart Association class IIIIV congestive heart failure No hemodynamically significant valvular heart disease No myocardial infarction within past 6 month No active angina pectoris No uncontrolled ventricular arrhythmia No stroke within past year No know cerebrovascular disease No significant cardiac disease echocardiogram , stress test , risk assessment cardiologist ( patient suspect cardiac disease history physical exam ) Immunologic No known HIV positivity No immunosuppressive disorder , include chronic disorder Other Not pregnant Negative pregnancy test Potassium ≥ 3.0 mEq/L ( may replace ) Able tolerate modest blood volume electrolyte shift leukapheresis No malignancy PRIOR CONCURRENT THERAPY : Biologic therapy Prior biologic therapy allow Other concurrent biologic therapy allow Chemotherapy See Disease Characteristics No concurrent chemotherapy Endocrine therapy No concurrent steroids 16 week study treatment Radiotherapy See Disease Characteristics No concurrent radiotherapy Surgery See Disease Characteristics Other Prior neoadjuvant adjuvant therapy surgically resect patient allow No concurrent shorter course immunosuppressive medication 16 week study treatment No concurrent chronic immunosuppressive medication Concurrent cyclooxygenase2 inhibitor allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>